Materials and Reagents

96-well black bottom plates (Greiner Bio-One GmbH, catalog number: 655209 )
Anti-human Fc capture biosensors (Pall Corporation, ForteBio^®, catalog number: 18-5060 )
Phosphate buffered saline (Life Technologies, Gibco^TM, catalog number: 100-10023 )
Monoclonal antibodies and hyperglycosylated core analytes (expressed in-house)

Equipment

Octet Red system (Pall Corporation, ForteBio^®, part number: 30-5048 )

Software

Data Analysis 6.2 evaluation software (Forte Bio)

Procedure

Biosensors are tips coated with proprietary biocompatible matrix that can bind to Fc region of human immunoglobulin with minimal non-specific binding. In a separate black bottom plate, the biosensors were hydrated in 200 μl PBS for 10 min at room temperature prior to the experiment. The sample plate was generated according to the template shown in Figure 1. The buffer wells were filled with 200 μl PBS. Selected monoclonal antibodies were diluted to 5 μg/ml in PBS and dispensed at a volume of 200 μl into each well of the loading column as indicated in the template. The H1 well was filled with 200 μl PBS. The analyte (HIV envelope core glycoprotein is used in the example shown in Figure 1) was 2-fold serially diluted in PBS starting from 1 μM to 31.25 nM in a separate plate and transferred in a 200 μl volume in the “association column” of the template as shown (Figure 1). The sensor plate (plate with bio-sensors) and sample plate (plate with other reagents, as shown in Figure 1) were then inserted into the Octet Red machine and a basic kinetic measurement experiment was performed as follows:

The sensors were dipped in buffer for equilibration.
The sensors were transferred to the sensor plate and monoclonal antibodies were captured on the sensors at 1,000 rpm for 60 sec.
Sensors were washed in PBS and a stable baseline was achieved at 1,000 rpm for 60 sec.
The antibody-immobilized sensors were immersed in analyte-containing wells for 600 sec at 1,000 rpm to allow potential association of analyte with a given monoclonal antibody.
Bio-sensors were next transferred to and immersed in wells containing a volume of 200 μl PBS at 1,000 rpm for 600 sec for the dissociation of the bound analyte.
During each run two reference sensor were included, first where at the association step the sensors were immersed in PBS buffer as an analyte control (to be used for subtraction during analysis of the raw data) and second where no antibody was immobilized on the sensor and a 500 nM analyte was used during the association phase to assess the level of non-specific binding of analyte to the anti-human Fc capture sensors, if any such interactions were detected.
The data was analyzed with Data Analysis 6.2 evaluation software. The data was processed using analyte control reference well for subtraction from the experimental data curves, aligning Y-axis to the baseline, and applying Savitzky-Golay as the filtering process. Next, the association and dissociation response curves were plotted using 1:1 model and global full curve fitting to compute the K_a, K_d, and K_D values.

Figure 1. Schematic diagram of sample plate and representative data of a kinetic experiment by bio-layer interferometry (BLI). A. Sample plate setup for measuring the kinetics of binding interaction between a monoclonal antibody and its ligand. REF 1 well is filled with PBS and used for reference subtraction. REF 2 well is a control experiment to check the non-specific binding of an analyte to the Fc capture sensors. B. The binding kinetics of a broadly neutralizing HIV 1 monoclonal antibody to a stable core envelope protein at various concentrations of the analyte. The black lines represent the theoretical Langmuir fits generated by 1:1 binding kinetics. The colored lines are the experimental curves for association and dissociation of the binding event.

Acknowledgments

This protocol was previously used in Ingale et al. (2014).

References

Ingale, J., Tran, K., Kong, L., Dey, B., McKee, K., Schief, W., Kwong, P. D., Mascola, J. R. and Wyatt, R. T. (2014). Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies. J Virol 88(24): 14002-14016.